Antigen Express previously entered into an agreement with Mayo Clinic to work with Keith Knutson, an expert in the field of peptide vaccines in breast cancer.
The current agreement focuses on advancing an immunotherapeutic vaccine for melanoma into the clinic with Svetomir Markovic, a distinguished translational researcher with expertise in melanoma trials.
The immunotherapeutic melanoma vaccine was constructed using the same technology as was employed for AE37, Antigen Express’s most advanced peptide vaccine currently in Phase II clinical trials in patients with breast cancer.
Eric von, president of Antigen Express, said: “We are excited to begin the process of moving this into the clinic with Dr Markovic. He is an outstanding investigator with whom we are fortunate to have the opportunity to work.”